Can Gilead Stock Outrun Regeneron In The Next Rally?

Core Insights - Regeneron Pharmaceuticals stock increased by 19% over the past month due to strong third-quarter earnings and robust sales of its flagship drugs, Dupixent and Libtayo [1] - Gilead Sciences presents a more favorable investment option compared to Regeneron, with superior revenue growth and profitability metrics [3][4] Revenue Growth Comparison - Gilead Sciences reported a quarterly revenue growth of 3.0%, while Regeneron achieved only 0.9% [3] - Over the last three years, Gilead's average revenue growth was 2.3%, surpassing Regeneron's 1.4% [3] Profitability Metrics - Gilead outperformed Regeneron in profitability, with a last twelve months margin of 38.3% and a three-year average margin of 39.2% [4] Valuation and Performance Overview - A detailed comparison of financials indicates that Gilead's fundamentals are stronger in terms of growth, margins, momentum, and valuation multiples compared to Regeneron [4][5] Investment Strategy - Asset allocation is recommended as a more prudent strategy than merely selecting individual stocks, with Trefis' High Quality Portfolio showing positive results during market downturns [5][8]